Early Trial Shows Stem Cell Therapy Halves Knee Osteoarthritis Pain and Triggers Cartilage Repair

For millions of adults living with moderate knee osteoarthritis, the treatment pathway is a frustrating waiting game. Available therapies like corticosteroid injections only mask the pain, leaving patients to endure progressive joint deterioration until they qualify for a total knee replacement.

A novel experimental therapy may soon bridge that gap. Results from a Phase IIa clinical trial show that a single injection of a stem cell combination therapy, dubbed OSCA, can halve knee pain while triggering early signs of cartilage regeneration.[1][2]

The findings were presented on November 11 at the American College of Rheumatology Convergence 2026 meeting in Orlando. If the results hold up in larger trials, the treatment could become the first genuine disease-modifying therapy for knee osteoarthritis.[1][2]

Developed by South Korean firm Kangstem Biotech, OSCA is a biopharmaceutical combination product. It pairs allogeneic mesenchymal stem cells derived from human umbilical cord blood with an acellular cartilage matrix harvested from pigs, which acts as a structural scaffold.[1]

Rapid Symptom Relief

The multicenter, randomized, placebo-controlled trial enrolled 113 patients with moderate knee osteoarthritis. Participants were randomly assigned to receive a placebo, a mid-sized dose of 50 million cells, or a high dose of 100 million cells via a single intra-articular injection.[2]

At the six-month mark, patients receiving the stem cell therapy reported dramatic improvements in their daily symptoms. Self-rated pain scores on a 100-millimeter Visual Analog Scale fell by 44.4 points in the mid-dose group and 37.7 points in the high-dose group.[2]

While the placebo group also experienced a 14.9-point reduction in pain, the stem cell injections maintained a clinically and statistically significant advantage. Researchers noted that the separation in pain relief between the treatment and placebo groups became apparent just four weeks after dosing.[1][2]

Functional assessments mirrored the pain reductions. Scores on the Western Ontario and McMaster Universities Osteoarthritis Index and the Knee Injury and Osteoarthritis Outcome Score both improved by roughly 25 points, representing a 50 percent improvement from baseline.[1]

Using the OMERACT-OARSI responder criteria, which measures clinically meaningful improvement, the trial found that 78.4 percent of the mid-dose group and 77.1 percent of the high-dose group responded to the therapy. Only 38.9 percent of the placebo group met that threshold.[2][3]

Signs of Cartilage Regeneration

While symptom relief is common in early arthritis trials, structural repair is the elusive holy grail. To assess joint preservation, researchers utilized advanced magnetic resonance imaging techniques, including the Magnetic Resonance Observation of Cartilage Repair Tissue scoring system.[1][2]

The mid-dose group demonstrated a statistically significant 2.7-point increase in their total MOCART scores, indicating an improvement in cartilage repair tissue. In contrast, the placebo group saw their scores decrease by 0.9 points over the same 24-week period.[2]

The trial also evaluated bone marrow health using the Whole-Organ Magnetic Resonance Imaging Score. Although total WORMS scores did not differ significantly across the entire cohort, a subregional analysis revealed significant improvements in marrow abnormalities for the high-dose group.[2][3]

AI

"For patients with moderate knee osteoarthritis, a single injection that provides substantial pain relief sustained through 6 months would be clinically meaningful," lead researcher Dr. Jae-Young Park of Cha University told Healio.[2]

"More broadly, these results are an encouraging sign for osteoarthritis therapies that aim to repair damaged joint tissue; not only relieve symptoms," Park added. "They also give us a strong basis for designing phase 2b and 3 trials."[2]

Safety and Biological Mechanism

The OSCA therapy was well-tolerated throughout the six-month study window. Researchers reported no treatment-related serious adverse events, and no patients discontinued their participation in the trial due to complications from the injection.[2][3]

Mild to moderate adverse drug reactions did occur, affecting 7.9 percent of patients in the mid-dose group and 21.1 percent of those receiving the high dose. No adverse reactions were recorded among the patients who received the placebo injection.[2]

The treatment's dual-action mechanism is designed to address multiple facets of joint degradation simultaneously. The umbilical cord blood-derived stem cells secrete anti-inflammatory and regenerative signals, while the acellular matrix provides a physical framework for new tissue to anchor and grow.[1]

Blood and urine tests supported this biological activity. Patients in the high-dose group showed statistically significant reductions in serum inflammatory markers, including tumor necrosis factor-alpha and interleukin-1, compared to the placebo cohort.[2]

The therapy also significantly lowered levels of urinary CTX-II, a well-established biomarker for cartilage turnover and degradation. This biochemical shift aligns with the MRI findings, suggesting that the treatment actively slows the breakdown of existing joint tissue.[2]

A Crowded Biotech Race

The promising data arrives in a therapeutic landscape littered with high-profile failures. Over the past two decades, dozens of experimental disease-modifying osteoarthritis drugs have failed in late-stage clinical trials, unable to prove structural benefits that outpace a placebo.[1]

The challenge has always been proving that a drug can do more than just mask inflammatory pain. By targeting the synovium, subchondral bone, and sensory neurons simultaneously, OSCA attempts to alter the underlying disease process rather than just its symptoms.[1]

The global market for a true disease-modifying arthritis therapy is massive. With no approved treatments that can reverse joint damage, patients currently rely on a combination of physical therapy, weight management, and temporary pain injections to delay surgical intervention.[1][2]

If the structural improvements seen in this Phase IIa trial can be replicated and sustained, the financial and clinical implications would be staggering. A successful regenerative therapy could fundamentally disrupt the orthopedic surgery market and reduce the volume of joint replacements.[1]

The Path to Clinical Use

Despite the encouraging early results, orthopedic specialists caution that the therapy remains in the preliminary stages of clinical validation. A six-month follow-up window is relatively short for a disease that progresses over decades, and MRI changes do not always guarantee long-term joint survival.[3]

AI

To address these limitations, the participants in the current trial will be monitored for an additional six months. Researchers have also planned a five-year extension study to track whether the single injection provides durable joint preservation over the long term.[3]

The ultimate regulatory test will require large-scale Phase III trials involving hundreds of patients across multiple clinical centers. These pivotal studies must definitively prove that the stem cell therapy can delay or prevent the need for total knee arthroplasty.[1][2]

Until those rigorous trials are completed and regulatory bodies grant approval, OSCA remains an investigational product. For now, the data offers a compelling glimpse at a future where degenerative joint disease might be reversed rather than merely managed.[1]